STOCKS TELEGRAPH

Tag: NASD:PRTG

  • Strong Pre-Hour Activity For Portage Biotech (PRTG) Stock

    Strong Pre-Hour Activity For Portage Biotech (PRTG) Stock

    The revelation of encouraging preclinical data caused Portage Biotech Inc.’s (NASDAQ: PRTG) stock price to spike higher. PRTG shares were trading at $12.90 as of the most recent premarket session, indicating a noteworthy 52.66% increase.

    Positive PORT-7 Data Is Revealed

    Portage Biotech (PRTG) unveiled confirmatory preclinical efficacy results for the selective adenosine A2B receptor inhibitor PORT-7 (TT-4). Dr. Luciano Mutti, a world-renowned expert in mesothelioma from the University of L’Aquila, Italy’s Department of Applied Clinical Sciences and Biotechnology, conducted the investigation.

    The American Association for Cancer Research (AACR) Annual Meeting, which is being held today at the McCormick Place Convention Center in Chicago, is where Dr. Mutti is expected to give the comprehensive results.

    Better Preclinical Trial Outcomes

    PORT-7 demonstrated better single-agent efficacy than anti-PD1 antibody therapy alone in a murine mesothelioma model. Additionally, the anti-PD1 and PORT-7 combination treatment worked better than each monotherapy, indicating a potent synergistic impact.

    Tumors from mice treated with the mixture showed the development of tertiary lymphoid structures, according to immunohistochemical examination, suggesting a positive immune response. An increase in immune effector cells, which suggested a better anti-tumor immunological milieu, further supported this.

    These findings present a promising opportunity for developing therapeutic approaches against immune-resistant malignancies, given the aggressive character of mesothelioma and the dearth of efficient therapies.

    Progressing Strategically Toward Clinical Trials

    With PORT-7, Portage Biotech is getting ready to start a first-in-human clinical trial. At the same time, PRTG is advancing PORT-6, a strong and specific A2A adenosine receptor inhibitor, into the dosage escalation phase.

    The current ADPORT-601 study is planning to co-administer PORT-6 and PORT-7, which would be the first time two highly specific A2A and A2B antagonists are used together in human patients.

    By using this novel strategy, Portage Biotech (PRTG) hopes to completely prevent adenosine-induced immunosuppression in the tumor microenvironment, boosting anti-tumor immune responses and increasing the effectiveness of immunotherapy for a wider variety of solid tumors.

  • Portage Biotech (PRTG) Shares Skyrocket In Pre-Hour Trading

    Portage Biotech (PRTG) Shares Skyrocket In Pre-Hour Trading

    The stock value of Portage Biotech Inc. (NASDAQ: PRTG) skyrocketed following the release of promising preclinical results. PRTG stock was selling at $9.64 as of the most recent pre-market check, representing a startling 103.81% rise.

    Innovation in the Treatment of Mesothelioma

    Portage Biotech presented fresh preclinical results on PORT-7 (TT-4), a selective Adenosine A2B receptor inhibitor, at the 2025 European Lung Cancer Congress (ELCC), which took place in Paris from March 26 to 29. Dr. Luciano Mutti of Gruppo Italiano Mesotelioma e Oncologia Ambientale conducted the study, which showed encouraging anticancer activity.

    Results showed that PORT-7 significantly suppressed tumors when taken alone. More significantly, in a mouse mesothelioma model, it suppressed tumor development by over 90% when paired with an anti-PD1 antibody.

    Furthermore, immunohistochemical examination of treated tumors revealed a significant infiltration of immune effector cells that are CD3 and CD45 positive. These results demonstrate PORT-7’s potential in tackling immune resistance pathways, which is important given the aggressive nature of mesothelioma and the lack of viable treatment alternatives.

    Advancements in Strategic Clinical Practice

    PORT-7’s first-in-human clinical study is currently being prepared by Portage Biotech. At the same time, the business is developing PORT-6, a strong and specific A2A adenosine receptor inhibitor, in its dose escalation phase.

    As part of the ADPORT-601 study, plans are underway to co-administer PORT-6 and PORT-7, which would be the first time that patients would receive both highly specific A2A and A2B antagonists. By completely preventing adenosine-induced immunosuppression in the tumor microenvironment, this dual-inhibitor approach may improve the effectiveness of immunotherapy in solid tumors.

    PORT-6 Clinical Trials Resuming

    Following a brief halt due to financial limitations, Portage Biotech has reopened patient recruitment in the fourth and final cohort of its Phase 1b ADPORT-601 study for PORT-6. The continuance of the experiment demonstrates faith in the therapeutic potential and safety of PORT-6.

    In order to advance its immunotherapy pipeline, PRTG will evaluate the feasibility of expanding the research to include PORT-7 and combo arms when this phase is over. These recent advancements put Portage Biotech at the forefront of immuno-oncology innovation and reinforced its dedication to developing cutting-edge medicines for tumors that are difficult to cure.

  • Pre-Market Surge: Portage Biotech (PRTG) Sees Upward Movement

    Pre-Market Surge: Portage Biotech (PRTG) Sees Upward Movement

    Shares of Portage Biotech Inc. (NASDAQ: PRTG) are experiencing upward momentum, rising 4.31% to $4.60 during the pre-market session. This increase follows the announcement of a significant equity transaction. Over the past week, the stock has seen a 5.00% gain. Investors seeking comparable biotechnology stocks with a market capitalization under $200 million and gains exceeding 5% can explore options via our ST screener link.

    Equity Financing and Corporate Utilization

    Portage Biotech has successfully completed a private placement, raising $2.15 million through the sale of 524,390 ordinary shares at $4.10 per share. This transaction, executed at the official Nasdaq closing price on January 22, 2025, was funded by two Portage directors. PRTG intends to utilize the proceeds for working capital and other corporate purposes across its subsidiaries, reinforcing its financial stability and operational expansion.

    Strategic Relaunch of Cyncado Therapeutics

    In a strategic move, Portage Biotech has restructured one of its subsidiaries, relaunching it as an independently managed entity under the name Cyncado Therapeutics Inc. This newly rebranded company will focus on advancing best-in-class adenosine receptor antagonists. As Chief Executive Officer, Peter Molloy, a seasoned professional in the field, will be responsible for obtaining outside funding and spearheading clinical research projects for the subsidiary’s potential medicinal portfolio.

    Immuno-Oncology Advancement Via the Adenosine Pathway Investigate

    The development of A2a and A2b receptor antagonists, which are intended to provide strong, targeted, and long-lasting suppression of immune suppression signals inside the tumor microenvironment, will be led by Cyncado Therapeutics. These treatments aim to completely inhibit immune evasion pathways, which will strengthen the immune system’s capacity to generate a strong anti-tumor response. They are designed to be administered twice to maximize synergy.

    Portage Biotech is still dedicated to increasing shareholder value and realizing the full potential of its assets. The business thinks it can optimize the effects of its adenosine program by making Cyncado a stand-alone firm. Moving forward, Cyncado Therapeutics aims to generate proof-of-concept data, further solidifying the role of its innovative treatments in the evolving landscape of oncology.

  • Portage Biotech (PRTG) Stock Soars Amid Strategic Transaction

    Portage Biotech (PRTG) Stock Soars Amid Strategic Transaction

    Following a significant strategic decision, the stock value of Portage Biotech Inc. (NASDAQ: PRTG) has increased significantly, with shares rising by 124.62% to $7.30. This comes after a significant milestone in PRTG’s continuous efforts to increase shareholder value—the announcement of a contract to sell its fully owned subsidiary, iOx Therapeutics, Ltd.

    Portage Biotech Inked Strategic Collaboration with Immunova

    Immunova, LLC, a Connecticut-based biotechnology business, and Portage Biotech have signed a Letter of Intent (LOI). Through the negotiation of a final option agreement, Immunova or its affiliate will be able to purchase iOx Therapeutics.

    Positive early-stage clinical outcomes have been produced by iOx, which focuses on the development of liposomal iNKT agonists, especially with their flagship candidate, PORT-2. This purchase supports Portage Biotech’s plan to simplify its line of business while accelerating the development of potential treatments.

    PRTG is Streamlining Assets and Unlocking Shareholder Value

    The decision to partner with Immunova reflects Portage Biotech’s broader efforts to optimize its assets. By selling off iOx Therapeutics, the company hopes to increase shareholder value while accelerating the clinical development of novel treatments. As PRTG looks to optimize returns via prudent asset management, this deal also marks a significant turning point in the company’s continuous assessment of its strategic options.

    Portage Biotech’s Focus on Clinical Development and Funding Needs

    Earlier this year, Portage Biotech had announced plans to evaluate various strategic options to extend its financial runway. The company’s Board of Directors also decided to pause further enrollment in its ADPORT-601 clinical trial for the development of adenosine antagonists, including PORT-6 and PORT-7.

    This move was made in light of the company’s current funding needs and the broader market conditions for capital raising. PRTG’s commitment to exploring strategic alternatives remains steadfast, with possibilities ranging from asset sales to company mergers or restructurings, ensuring the continued evolution of the company’s pipeline and value proposition.